Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Nordion Appoints Mr. Grant Gardiner as SVP and General Counsel

Published: Tuesday, January 29, 2013
Last Updated: Tuesday, January 29, 2013
Bookmark and Share
Mr. Gardiner will serve as the Corporation's legal officer responsible for all global legal matters, effective March 18, 2013.

"We are very pleased to welcome Grant to the Nordion management team. With more than 19 years of experience, Grant is a seasoned lawyer with a strong understanding of business and global market dynamics. His proven expertise in leading cross-listed, publicly traded companies through complex legal, governance and compliance landscapes with a business focus will be a significant asset to Nordion,” said Mr. Steve West, Chief Executive Officer, Nordion Inc. “Grant is expected to play an instrumental role in the execution of our business strategy globally.”

Mr. Gardiner joins Nordion from Research in Motion Limited (RIM) where he currently serves as Vice-President, Associate General Counsel and acted as Corporate Secretary to RIM’s Board of Directors for approximately four years. During his tenure at RIM, which began in 2008, Grant has advised on securities matters, mergers & acquisitions, ethics and compliance programs as well as Board and Corporate Governance matters.

With leadership roles at other leading global, publicly-traded companies such as Cognos Inc. (now IBM) and JDS Uniphase, Mr. Gardiner’s experience includes mergers and acquisitions, corporate governance, commercial transactions, as well as securities and anti-corruption law. He holds a Bachelor of Business Administration from the University of Prince Edward Island (1988), an L.L.B. from Osgoode Hall Law School (1991) and was admitted to the Ontario Bar in 1993.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,600+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
ASMS 2016: Targeting Mass Spectrometry Tools for the Masses
The expanding application range of MS in life sciences, food, energy, and health sciences research was highlighted at this year's ASMS meeting in San Antonio, Texas.
Long-Term Culturing of Adult Stem Cells
A new procedure developed by Harvard Stem Cell Institute researchers (HSCI) at Massachusetts General Hospital (MGH) may revolutionize the culturing of adult stem cells.
Solutions for Biotherapeutic Characterization
Innovation to speed the routine.
Plant-Based Vaccine Among Front Runners In Search For New Polio Jab
A researcher from Norwich is part of a consortium that has been awarded $1.5 million to develop safer polio vaccines, using a new technique developed at the John Innes Centre.
Harnessing Helpful Microbes
Seeking to further harness microbes’ many uses, the federal government has launched the National Microbiome Initiative (NMI) to “foster the integrated study of microbiomes across different ecosystems.”
What Makes a Good Scientist?
It’s the journey, not just the destination that counts as a scientist when conducting research.
A New Approach to Chemical Synthesis
Communesins, originally found in fungus, could hold potential as cancer drugs.
Better Animal Model to Improve HIV Vaccine Development
Penn study identifies a new tool to produce better HIV vaccine designs.
First Large-Scale Proteogenomic Study of Breast Cancer
The study offers understanding of potential therapeutic targets.
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,600+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!